Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, BioCryst Pharmaceuticals's average EBITDA Per Share Growth Rate was -496.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioCryst Pharmaceuticals was 41.90% per year. The lowest was -63.70% per year. And the median was 2.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BioCryst Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
BCRX vs PBH, SUPN, AMLX: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
BioCryst Pharmaceuticals (BCRX) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioCryst Pharmaceuticals and its competitors. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 809 companies in the Drug Manufacturers industry.
Is BioCryst Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
BioCryst Pharmaceuticals' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 809 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' 3-Year EBITDA Growth Rate compare to PBH and SUPN?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #999999 out of 809 companies for 3-Year EBITDA Growth Rate. This places BioCryst Pharmaceuticals in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.60, compared to a current price of $9.74 — trading 22.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. BioCryst Pharmaceuticals' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.74 is trading 22.7% below its estimated GF Value™ of $12.60.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $12.60 vs. price of $9.74 (22.7% below fair value)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
69GF Score
Get the complete analysis for BCRX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
